NASDAQ:ALT Altimmune (ALT) Stock Price, News & Analysis $2.78 -0.06 (-2.15%) As of 03:22 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Altimmune Stock (NASDAQ:ALT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Altimmune alerts:Sign Up Key Stats Today's Range$2.76▼$2.8950-Day Range$2.59▼$3.1652-Week Range$2.56▼$6.44Volume1.02 million shsAverage Volume4.20 million shsMarket Capitalization$540.43 millionP/E RatioN/ADividend YieldN/APrice Target$15.71Consensus RatingModerate Buy Company Overview Altimmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions. Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose. This candidate is being advanced in collaboration with the University of Alabama at Birmingham and is supported by the National Institute of Allergy and Infectious Diseases. In parallel, Altimmune’s HepTcell program aims to treat chronic hepatitis B by eliciting targeted T-cell responses capable of clearing infected liver cells. Altimmune’s AdCOVID™ platform uses a replication-incompetent adenovirus vector to deliver vaccine antigens directly to the nasal mucosa, and it is also under evaluation for additional respiratory pathogens, including coronaviruses. The company maintains a pipeline of preclinical programs in liver and metabolic diseases, reflecting its commitment to harnessing immunotherapy and vaccine design across multiple therapeutic areas. The company’s leadership team combines extensive scientific expertise and operational experience in vaccine research and development. Through a strategic blend of translational science and external partnerships, Altimmune seeks to advance innovative therapies that improve patient outcomes and address global health challenges.AI Generated. May Contain Errors. Read More Altimmune Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreALT MarketRank™: Altimmune scored higher than 36% of companies evaluated by MarketBeat, and ranked 652nd out of 835 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAltimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAltimmune has a consensus price target of $15.71, representing about 460.2% upside from its current price of $2.81.Amount of Analyst CoverageAltimmune has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Altimmune's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Altimmune are expected to remain at ($0.64) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Altimmune's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.89% of the float of Altimmune has been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 8.07.Change versus previous monthShort interest in Altimmune has recently increased by 13.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 7 people have searched for ALT on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows9 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have not sold or bought any company stock.Percentage Held by Insiders1.60% of the stock of Altimmune is held by insiders.Percentage Held by Institutions78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Altimmune's insider trading history. Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALT Stock News HeadlinesAltimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - UpgradeJuly 7, 2026 | seekingalpha.comLeerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics MarketJuly 5, 2026 | finance.yahoo.comElon's next move will be bigger than the IPO – and it could happen any day nowHedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning streak - says the SpaceX IPO wasn't the main event. It was the trigger. He's identified what he calls the 'Final Phase of Elon's Master Plan,' and one specific ticker he believes could see billions forced into it within days. It's not SpaceX, Tesla, or any company you'd associate with Elon Musk. Larry is revealing the ticker free today.July 24 at 1:00 AM | Brownstone Research (Ad)Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?June 24, 2026 | finance.yahoo.comAltimmune moving headquarters from Gaithersburg to New JerseyJune 17, 2026 | bizjournals.comAltimmune Relocates Corporate Headquarters to Morristown, New JerseyJune 16, 2026 | tipranks.comAltimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comAltimmune sets pemvidutide's phase 3 MASH playbook as AUD data nearJune 10, 2026 | msn.comSee More Headlines ALT Stock Analysis - Frequently Asked Questions How have ALT shares performed this year? Altimmune's stock was trading at $3.61 on January 1st, 2026. Since then, ALT stock has decreased by 22.3% and is now trading at $2.8050. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) announced its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.07. Altimmune had a negative trailing twelve-month return on equity of 42.57% and a negative net margin of 214,860.98%. Read the conference call transcript. When did Altimmune's stock split? Shares of Altimmune reverse split on Friday, September 14th 2018.The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Altimmune's major shareholders? Altimmune's top institutional investors include Hennion & Walsh Asset Management Inc. (0.27%). Insiders that own company stock include David Drutz, Jerome Benedict Durso, Gregory L Weaver, Wayne Pisano, John Gill and Diane Jorkasky. View institutional ownership trends. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include Invesco QQQ (QQQ), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE) and SPDR S&P 500 ETF Trust (SPY). Company Calendar Last Earnings5/13/2026Today7/24/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ALT's financial health is in the Red zone, according to TradeSmith. ALT has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALT CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees50Year Founded1997Price Target and Rating Average Price Target for Altimmune$15.71 High Price Target$24.00 Low Price Target$10.00 Potential Upside/Downside+464.2%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.09 million Net Margins-214,860.98% Pretax Margin-253,002.78% Return on Equity-42.57% Return on Assets-35.57% Debt Debt-to-Equity Ratio0.12 Current Ratio29.56 Quick Ratio29.56 Sales & Book Value Annual Sales$40 thousand Price / Sales13,539.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.99 per share Price / Book1.40Miscellaneous Outstanding Shares194,470,000Free Float191,362,000Market Cap$541.60 million OptionableOptionable Beta0.25 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ALT) was last updated on 7/24/2026 by MarketBeat.com Staff. From Our PartnersBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredElon's next move will be bigger than the IPO – and it could happen any day nowHedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning s...Brownstone Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredThe market told you. In writing. Early.Some trading losses are surprises. Others are scheduled months, even a year, in advance and published for free...Profits Run | SponsoredWill you miss the REAL SpaceX opportunity?When SpaceX went public, retail traders rushed to buy the stock itself. Millionaire trader Tim Bohen says that...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
